The present invention provides a method of recovering an extracellular vesicle from an extracellular vesicle-containing sample. More specifically, the present invention provides a method of recovering the extracellular vesicle that includes separating the extracellular vesicle from the extracellular vesicle-containing sample in the presence of a polymer.

The present invention provides a method of recovering an extracellular vesicle from an extracellular vesicle-containing sample. More specifically, the present invention provides a method of recovering the extracellular vesicle that includes separating the extracellular vesicle from the extracellular vesicle-containing sample in the presence of a polymer.

The present application discloses a composition for use in diagnosing cancer, the composition comprising: an antibody or antigen-binding fragment thereof that specifically binds to a BAG2 polypeptide or fragment thereof.

Novel anti-CD8 (cluster of differentiation 8 alpha) antibodies and antigen-binding fragments thereof, a fusion protein including the anti-CD8 antibodies and antigen-binding fragments thereof, and a nucleic acid molecule encoding the anti-CD8 antibodies and antigen-binding fragments thereof. Also, pharmaceutical compositions including the anti-CD8 antibodies and antigen-binding fragments thereof. Further, methods using the anti-CD8 antibodies and antigen-binding fragments thereof for treating CD8-related diseases and in vitro methods in which CD8a-expressing cells are depleted in a sample or in which CD8 is detected or quantified in a sample.

Novel anti-CD8 (cluster of differentiation 8 alpha) antibodies and antigen-binding fragments thereof, a fusion protein including the anti-CD8 antibodies and antigen-binding fragments thereof, and a nucleic acid molecule encoding the anti-CD8 antibodies and antigen-binding fragments thereof. Also, pharmaceutical compositions including the anti-CD8 antibodies and antigen-binding fragments thereof. Further, methods using the anti-CD8 antibodies and antigen-binding fragments thereof for treating CD8-related diseases and in vitro methods in which CD8a-expressing cells are depleted in a sample or in which CD8 is detected or quantified in a sample.